ワクチンの世界市場 - 2025～2032年

ワクチンの世界市場は2024年に770億1,000万米ドルに達し、2032年には1,088億2,000万米ドルに達すると予測され、予測期間2025年のCAGRは3.9%で成長します。

ワクチンは、ウイルスや細菌のような特定の病原体を認識し、それと闘うために身体の免疫システムを刺激するように設計された生物学的物質です。通常、病原体の弱体化または不活性化された形態、または病原体の一部（タンパク質など）が含まれており、病気を引き起こすことなく免疫反応を引き起こします。この反応により、再び病原体に遭遇した場合、素早く病原体を認識し、闘うことができるよう身体が準備され、免疫力が備わります。

ワクチンは、感染症を予防し、その蔓延を抑え、弱い立場にある人々を守るために極めて重要です。予防接種を受ける人の割合は増加しています。政府の取り組みは、感染症の増加を防ぐために、まだ予防接種を受けていない人々を対象としています。例えば、ユニセフの報告書によると、毎年2,600万人近くの新生児と3,400万人の妊婦が予防接種の対象となっており、全国で1,300万回以上の予防接種が実施され、子供と妊婦に予防接種が行われています。

市場力学：

促進要因と阻害要因

ワクチンの開発の高まり

ワクチンの開発進展は、より広範な疾患に対応する新しく改良されたワクチンの導入につながるため、世界のワクチン市場の主な促進要因となっています。科学の進歩が進むにつれ、研究者は特定のがん、マラリア、新興感染症など、かつてはターゲットとすることが困難であった疾患に対するワクチンを開発しています。このようにワクチンの範囲が広がることで、より多くの人々がより広範な病気からの保護を求めるようになり、市場の需要が高まっています。

世界中で新しいワクチンソリューションの承認数が増加しており、これが市場全体の成長に寄与すると期待されています。例えば、2023年9月、ファイザー社とBioNTech SEは、両社のOmicron XBB.1.5適応一価COVID-19ワクチンについて、米国食品医薬品局（FDA）が12歳以上の個人を対象とした生物製剤追加承認申請を承認し、6カ月から11歳までの個人を対象とした緊急使用許可を与えたと発表しました。今シーズンのワクチンは、5歳以上のほとんどの人に1回接種の適応があります。

さらに、様々な感染症や疾病の増加に伴い、新たなワクチンの必要性と開発が増加しています。例えば、2024年の世界保健機関（WHO）と米国疾病対策予防センター（CDC）の新たな推計によると、2023年の麻疹の患者数は全世界で推定1,030万人となり、2022年から20％増加しました。これは、COVID-19パンデミック時の定期予防接種の混乱によるところが大きいです。予防接種の回数を増やし、個人に幅広い選択肢を提供するため、企業は先進的なソリューションを革新しており、市場全体の成長に寄与しています。

さらに、mRNAワクチンのようなワクチン技術の革新は、ワクチンをより効果的で、製造しやすく、迅速に配布できるものにしています。こうした開発は公衆衛生の成果を高めるだけでなく、ワクチン産業への投資を誘致し、世界のワクチン市場のさらなる成長に拍車をかけています。

代替治療法との競合

抗ウイルス薬やモノクローナル抗体などの新しい治療法が登場すると、ワクチンが一般的に扱う疾患の予防や治療に効果的なソリューションが提供されるため、代替治療との競合は世界のワクチン市場にとって大きな抑制要因となっています。これらの治療法は、多くの場合、感染発生後に効果を発揮するため、ワクチン接種と比較して、より即効性があり、利便性の高い選択肢であると思われるため、魅力的です。さらに、これらの治療がワクチンよりも安価であったり、アクセスしやすかったりする場合、特に低所得者層では、人々は予防措置よりもそちらを選ぶかもしれません。このような嗜好の変化は、特に代替治療がより効果的で、手ごろな価格で、より簡単に使用できると認識された場合、ワクチン需要を減少させる可能性があります。その結果、こうした代替療法の台頭が競合を生み、ワクチンの世界の普及を妨げ、ワクチン市場全体の成長を鈍化させる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • ワクチンの開発の高まり
  • 抑制要因
    • 代替治療法との競合
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 タイプ別

• 結合型ワクチン
• 不活化ワクチン
• 生弱毒化ワクチン
• 組み換えワクチン
• トキソイドワクチン
• ウィルスベクターワクチン
• その他

第7章 カテゴリ別

• 一価ワクチン
• 二価ワクチン
• 多価なワクチン

第8章 疾患適応症別

• 水疱瘡
• コレラ
• ジフテリア
• インフルエンザ
• 肝炎
• 麻疹
• おたふく風邪
• ポリオ
• 狂犬病
• その他

第9章 投与経路別

• 筋肉内
• 皮下
• 鼻腔内
• その他

第10章 エンドユーザー別

• 地域病院
• 病院
• 専門センター
• クリニック
• その他

第11章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第14章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd
• Dr. Reddy's Laboratories Ltd.
• Intas Pharmaceuticals
• Akron Biotech
• Sandoz Group AG
• ratiopharm GmbH
• Biocon Limited

第15章 付録

The global vaccines market reached US$ 77.01 billion in 2024 and is expected to reach US$ 108.82 billion by 2032, growing at a CAGR of 3.9% during the forecast period 2025-2032.

Vaccines are biological substances designed to stimulate the body's immune system to recognize and fight specific pathogens, like viruses or bacteria. They typically contain a weakened or inactivated form of the pathogen, or pieces of it (like proteins), that trigger an immune response without causing illness. This response prepares the body to quickly recognize and combat the pathogen if encountered again, providing immunity.

Vaccines are crucial for preventing infectious diseases, reducing their spread, and protecting vulnerable populations. There is a rising percentage of individuals receiving immunizations. The government initiatives are targeting the population who are yet to receive immunizations to prevent the rise of infectious diseases. For instance, according to the report by UNICEF, every year, nearly 26 million newborns and 34 million pregnant women are targeted for immunization, and over 13 million immunization sessions are held nationwide to vaccinate children and pregnant women.

Market Dynamics: Drivers & Restraints

Rising development of vaccines

The rising development of vaccines is a key driver for the global vaccine market as it leads to the introduction of new and improved vaccines that address a wider range of diseases. As scientific advancements continue, researchers are developing vaccines for diseases that were once difficult to target, such as certain cancers, malaria, and emerging infectious diseases. This expanded range of vaccines increases market demand, as more people seek protection against a broader spectrum of illnesses.

There is a growing number of approvals for the new vaccine solutions around the globe which is expected to contribute to the overall market growth. For instance, in September 2023, Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. This season's vaccine is indicated as a single dose for most individuals 5 years of age and older.

Furthermore, with the rising number of various infections and diseases the need and development for new vaccines is increasing. For instance, according to new estimates from the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) in 2024, worldwide, there were an estimated 10.3 million cases of measles in 2023, a 20% increase from 2022. This is largely due to disruptions in routine immunization during the COVID-19 pandemic. To increase the number of immunizations and create a wide range of options for individuals, companies are innovating advanced solutions, thus contributing to the overall market growth.

Moreover, innovations in vaccine technology, such as mRNA vaccines, are making vaccines more effective, easier to produce, and quicker to distribute. These developments not only enhance public health outcomes but also attract investment in the vaccine industry, fueling further growth in the global vaccine market.

Competition from alternative treatments

Competition from alternative treatments is a significant restraint for the global vaccines market because as new therapies like antiviral drugs, monoclonal antibodies, and other treatments emerge, they offer effective solutions for preventing or treating diseases that vaccines typically address. These treatments can be appealing because they often work after infection occurs, making them seem like a more immediate or convenient option compared to vaccination. Additionally, if these treatments are less expensive or easier to access than vaccines, especially in low-income regions, people may choose them over preventive measures. This shift in preference can reduce vaccine demand, particularly if alternative treatments are perceived as more effective, affordable, or simpler to use. As a result, the rise of these alternative therapies can create competition that hampers the global uptake of vaccines, slowing the overall growth of the vaccine market.

Segment Analysis

The global vaccines market is segmented based on type, category, disease indication, route of administration, end-user, distribution channel, and region.

Drug Type:

Conjugate vaccines segment is expected to dominate the global vaccine market share

Conjugate vaccines are a dominant segment in the global vaccine market due to their proven effectiveness in preventing serious bacterial infections, particularly in infants and young children. Vaccines like pneumococcal conjugate vaccines (PCV) and Hib vaccines have drastically reduced diseases such as pneumonia, meningitis, and sepsis. Their ability to enhance immune response, even in infants with immature immune systems, has made them a cornerstone of childhood immunization programs worldwide.

The growing adoption of these vaccines, supported by global health initiatives like GAVI, has expanded their reach to low- and middle-income countries, driving demand. As new conjugate vaccines continue to be developed, targeting a broader range of bacterial diseases, this segment is expected to maintain its stronghold in the global vaccine market. Companies are receiving product approvals by meeting the stringent regulations and the products are proving their efficacy and safety. For instance, in June 2024, Merck received the U.S. Food and Drug Administration (FDA) approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes and for the prevention of pneumonia caused by S. pneumoniae serotypes in individuals 18 years of age and older.

In April 2023, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for PREVNAR 20(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR. With the rising launches of the new conjugate vaccines and approvals, the conjugate vaccines are becoming the more widely preferred vaccines.

Geographical Analysis

North America holds a dominant share of the global vaccines market due to the combination of advanced research capabilities, strong pharmaceutical companies' presence, and government initiatives in the region. The United States, in particular, stands out as a leader in both vaccine innovation and production. The U.S. has been at the forefront of developing new vaccines for influenza, respiratory syncytial virus (RSV), and even newer threats as the country has major market players.

The rising number of vaccine launches is expected to significantly drive the growth of North America's vaccine market. The companies are developing novel solutions to reach the demand and requirements of the vaccines to address the increasing incidence of the diseases. For instance, in June 2022, June 2022, GSK plc received the US Food and Drug Administration (FDA) approval for Priorix (Measles, Mumps and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older. Priorix is currently licensed in more than 100 countries worldwide, including all European countries, Canada, Australia and New Zealand, with more than 800 million doses distributed to date.

The government initiatives and the funding for increasing research and development in the region are contributing to the market growth and encouraging companies to innovate advanced solutions. For instance, in October 2024, the Ministry of Health of the Kingdom of Cambodia launched a nationwide measles-rubella supplementary immunization activity (MR SIA) to protect over 1.5 million children aged 9 to 59 months (aged<5 years old), across 25 provinces. This increases the demand for the drugs that are being developed in the region, thus driving the region's market growth.

Asia Pacific is at the fastest growing pace in the global vaccines market share

Asia Pacific is currently experiencing the fastest growth in the global vaccine market. The growth is attributed to the increasing investments in R&D Activities, rising innovation of new vaccines, rising campaigns by the governments and the rising strategic collaborations among companies.

Companies in the region are developing vaccines with various applications and are developing innovatively. For instance, in October 2023, Mylab and Serum Institute of India launched Nasovac S4, India's first needle-free nasal influenza vaccine. It contains four influenza virus strains and is recommended for individuals above the age of 2. It aims to provide superior protection against influenza and enhance vaccination rates by offering a more comfortable.

Competitive Landscape

The major global players in the vaccines market include GSK plc., Merck & Co., Inc., Pfizer Inc., CSL, EMERGENT, Johnson & Johnson Services, Inc., AstraZeneca, Bavarian Nordic, Bharat Biotech and Serum Institute of India Pvt. Ltd. among others.

Key Developments

• In October 2024, the Ministry of Health of the Kingdom of Cambodia launched nationwide measles-rubella supplementary immunization activities (MR SIA) to protect over 1.5 million children aged 9 to 59 months (aged<5 years old), across 25 provinces. Gavi, the Vaccine Alliance is funding the Ministry of Health-led campaign with the World Health Organization (WHO), UNICEF, and the Clinton Health Access Initiative (CHAI) providing technical support.
• In September 2024, Zambia launched a measles vaccination campaign aimed at reaching four million children aged nine months to five years, following a drop in immunization coverage during the COVID-19 pandemic.
• In January 2024, NHS launched a catch-up campaign for missed MMR vaccines. Millions of parents and carers in England are being urged to book their children in for their missed measles, mumps, and rubella (MMR) vaccine as part of a major new NHS drive to protect children from becoming seriously unwell, as measles cases continue to rise across the country.
• In June 2024, Moderna, Inc. announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Vaccine Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Category
• 3.3. Snippet by Disease Indication
• 3.4. Snippet by Route of Administration
• 3.5. Snippet by End User
• 3.6. Snippet by Distribution Channel
• 3.7. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising development of vaccines
  • 4.1.2. Restraints
    • 4.1.2.1. Competition from alternative treatments
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Conjugate Vaccines*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Inactivated Vaccines
• 6.4. Live-attenuated Vaccines
• 6.5. Recombinant Vaccines
• 6.6. Toxoid Vaccines
• 6.7. Viral Vector Vaccines
• 6.8. Others

7. By Category

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 7.1.2. Market Attractiveness Index, By Drug Type
• 7.2. Monovalent Vaccines*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Bivalent Vaccines
• 7.4. Multivalent Vaccines

8. By Disease Indication

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 8.1.2. Market Attractiveness Index, By Disease Indication
• 8.2. Chickenpox*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cholera
• 8.4. Diphtheria
• 8.5. Influenza
• 8.6. Hepatitis
• 8.7. Measles
• 8.8. Mumps
• 8.9. Polio
• 8.10. Rabies
• 8.11. Others

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Intramuscular*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Subcutaneous
• 9.4. Intranasal
• 9.5. Others

10. By End User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.1.2. Market Attractiveness Index, By End User
• 10.2. Community Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Hospitals
• 10.4. Specialty Centers
• 10.5. Clinics
• 10.6. Others

11. By Distribution Channel

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.1.2. Market Attractiveness Index, By Distribution Channel
• 11.2. Hospital Pharmacy*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Retail Pharmacy
• 11.4. Online Pharmacy

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.9.1. U.S.
    • 12.2.9.2. Canada
    • 12.2.9.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.9.1. Germany
    • 12.3.9.2. U.K.
    • 12.3.9.3. France
    • 12.3.9.4. Spain
    • 12.3.9.5. Italy
    • 12.3.9.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.9.1. Brazil
    • 12.4.9.2. Argentina
    • 12.4.9.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.9.1. China
    • 12.5.9.2. India
    • 12.5.9.3. Japan
    • 12.5.9.4. South Korea
    • 12.5.9.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Market Positioning/Share Analysis
• 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

• 14.1. Pfizer Inc.*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Amgen Inc.
• 14.3. Johnson & Johnson Services, Inc.
• 14.4. F. Hoffmann-La Roche Ltd
• 14.5. Dr. Reddy's Laboratories Ltd.
• 14.6. Intas Pharmaceuticals
• 14.7. Akron Biotech
• 14.8. Sandoz Group AG
• 14.9. ratiopharm GmbH
• 14.10. Biocon Limited

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us